This page shows what was measured, who it was measured in, and what that does not settle.
What Exemestane does in the body
Advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies ( 14
From the FDA-approved label: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · NY22HMQ4BX · read 2026-08-29
Its recorded molecular formula is C20H24O2, weighing 296.41.
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 117 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
5-year Disease-free Survival
✗ The study did not show it
Who was studied
NCT00310180
How many people
10273
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
To compare recurrence free survival between two treatment groups.
✗ The study did not show it
Who was studied
NCT00279448
How many people
9779
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years
✗ The study did not show it
Who was studied
NCT00036270
How many people
9779
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Invasive Disease-Free Survival (IDFS)
✗ The study did not show it
Who was studied
NCT05514054
How many people
8000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Event-free Survival
✗ The study did not show it
Who was studied
NCT00066573
How many people
7576
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Invasive breast cancer-free survival (IBCFS)
✗ The study did not show it
Who was studied
NCT05952557
How many people
5511
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.11 registered measures of this kind. 6 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
quality of life
Measured
Things only a test, a scale or a device shows.
pfs in hemoglobin a1c less than 5 7 at baseline
Meaningful
Things that change how a life goes, not only a number.
disease free survival
relapse free survival
time to disease progression
event free survival
overall survival
progression free survival
5 year disease free survival
progression free survival based on independent radiologist
time to relapse
invasive disease free survival
and 1 more.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (27)
clinical benefit
overall response rate in both arms
time to progression expert evaluation committee assessment
clinical response
clinical response rate
pathological response for basal group 2
safety
clinical benefit response rate
who died
adverse drug reaction
dose limiting toxicity
pathologic complete response
treatment emergent adverse events
treatment emergent adverse events by severity
rate of clinical benefit according to recist
duration of response
adverse events
safety and tolerability in terms of number of adverse events
adverse events and serious adverse events
bioequivalence determined by statistical comparison cmax
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 24 hours hours
Read from the label, which states: “12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Exemestane is an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets, USP for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness in pediatric patients have not been established.”
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on findings in animal studies and its mechanism of action , exemestane tablets can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] .”
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information on the presence of exemestane in human milk, or on its effects on the breastfed infant or milk production.”
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
On people with reduced liver function, the label states: “The AUC of exemestane was increased in subjects with moderate or severe hepatic impairment (Childs-Pugh B or C) [see Clinical Pharmacology (12.3) ] .”
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
On people with reduced kidney function, the label states: “The AUC of exemestane was increased in subjects with moderate or severe renal impairment (creatinine clearance <35 mL/min/1.73 m 2 ) [see Clinical Pharmacology (12.3)] .”
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Sold as tablet, tablet, film coated, tablet, sugar coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Exemestane appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 10559 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
26 products list this as an active ingredient in the United States drug directory. 26 of them contain it and nothing else.
FDA National Drug Code directory · 72603-329 · read 2026-08-29
They are sold as powder, tablet, tablet, film coated and tablet, sugar coated, taken oral.
FDA National Drug Code directory · 72603-329 · read 2026-08-29
The regulator's established pharmacologic class for it is aromatase inhibitor [epc] and aromatase inhibitors [moa].
FDA National Drug Code directory · 72603-329 · read 2026-08-29
11 published labels name it as an active ingredient. 11 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · fab5468a-d5b7-45e3-b8b2-ed902fddd3a6 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · fab5468a-d5b7-45e3-b8b2-ed902fddd3a6 · read 2026-08-29
1 marketed supplement label lists this ingredient, classed as non-nutrient/non-botanical.
Those labels carry all other and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Exemestane is oral at 3 DOSAGE FORMS AND STRENGTHS Exemestane Tablets, USP are white colored, round, biconvex, film-coated tablets debossed with "X" on one side and "1" on other side., recorded as fda label in effect 2024-05-29 in the United States.
US prescribing information · 1841ec12-3f4f-4b87-b719-fd0b4d9eaffb · read 2026-08-30
Recorded price in US: 0.71774 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 9 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Exemestane studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Exemestane are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
10 documents were read for this substance.
RNAWiki source record
10 of them state the same halfLife, and they agree.
RNAWiki source record
10 of them state the same tMax, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
NY22HMQ4BX
RxNorm concept
310261
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
12 approved applications cover products containing this substance. The earliest was NDA020753, approved 19991021 to PFIZER.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Exemestane's largest trial (10273 people) and its longest (24 years) measure?
10273 people in Exemestane's largest registered study, 24 years in its longest registered window, measuring Changes in Senescence and Secondary Biomarkers, Including TMEM, Mena, and 67LR. ClinicalTrials.gov · 2026-09-01
114 phase2, 68 phase3, 34 phase1, 15 na or unstated, 10 na, 9 phase4; NCT00310180; 2030-09-30. Last human test completed 2026, NCT04572295.
Interpretation These counts include studies where Exemestane was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
114
phase3
68
phase1
34
na or unstated
15
na
10
phase4
9
1 more recorded row
Last recorded human testNCT04572295
2026-06-18
recorded 2026-09-01 · last checked 2026-09-04
Q3
From rat to human: where has Exemestane shown biomarker?
safety (2), accrual/recruitment (6), funding/business (5), sponsor decision unspecified (1) and other (19): Exemestane's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Unable to accrue subjects to the study after 2 years - closed per request by Data Monitoring Committee."; 33 of 237 registered studies
Show the evidence
Trial
NCT00057993
withdrawn; "Unable to accrue subjects to the study after 2 years - closed per request by Data Monitoring Committee."
NCT00066807
terminated; "Poor accrual, patients were followed until completion of 5 yrs treatment"
NCT00372996
terminated; "This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns."
NCT00417885
terminated; "See Detailed Description for Termination Reason"
NCT00573755
terminated; "lack of participant accrual"
NCT00674557
terminated; "Withdrawn as the clinical development of ATN-224 was terminated by the drug company who was providing ATN-224 for the study"
14 further recorded trials
NCT00776659
terminated; "See termination reason in detailed description."
NCT00793546
terminated; "See termination reason in detailed description."
NCT00810706
terminated; "Publication of MA17 results (similar trial in the extented adjuvant setting with letrozole)"
NCT00905021
terminated; "Sponsor withdrew support"
NCT01005641
withdrawn; "Study not started for administrative reasons"
NCT01121549
terminated; "See termination reason in detailed description."
NCT01149356
terminated; "Manufacturer discontinued drug development."
NCT01155063
terminated; "See Detailed Description"
NCT01239745
terminated; "See termination reason in detailed description."
NCT01240928
withdrawn; "Funding not available, study did not open to accrual and will not open in future"
NCT01240941
withdrawn; "Funding was not available"
NCT01303679
terminated; "Not reveal any significant difference between the 2 treatment arms"
NCT01305239
terminated; "See termination reason in detailed description."
NCT01484041
terminated; "Decision by company to cease development of dovitinib"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Exemestane used Aromasin (Exemestane) 25 mg tablets — over how long?
6 recorded entries; human; also "Aromasin (Exemestane) 25 mg tablets", "Exemestane 25 mg tablets", "Exemestane 25 mg"
Show the evidence
human
NCT01760980
Aromasin (Exemestane) 25 mg tablets
NCT01760980
Exemestane 25 mg tablets
NCT02646735
Exemestane 25 mg
NCT03024580
Exemestane 25 MG
NCT04852081
Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
NCT07706374
Exemestane 50 MG
recorded 2026-09-01 · last checked 2026-09-04
Q6
Exemestane's half-life is 24 hours — which schedules were studied?
24 hours, the half-life Exemestane's label states. openfda-label · 69abd0ff-b200-4d1a-b14a-80e980a8e781 · 2026-08-30
Show the evidence
half life
24 hours hours; 12.3 Pharmacokinetics Following oral administration to healthy postmenopausal women, plasma concentrations of exemestane decline polyexponentially with a mean terminal half-life of about 24 hours.
tmax
Absorption Following oral administration, exemestane appeared to be absorbed more rapidly in women with breast cancer than in the healthy women, with a mean t max of 1.2 hours in the women with breast cancer and 2.9 hours in healthy women.
metabolism
Metabolism Exemestane is extensively metabolized, with levels of the unchanged drug in plasma accounting for less than 10% of the total radioactivity.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of 5 year disease free survival, adverse drug reaction and adverse events did Exemestane's trials measure?
5 year disease free survival, adverse drug reaction and adverse events lead 40 outcome terms across Exemestane's trials. ClinicalTrials.gov · 2026-09-01
Interpretation time to disease progression, event free survival, overall response rate in both arms, time to progression expert evaluation committee assessment, clinical response and overall survival follow.
Show the evidence
disease free survival
1
relapse free survival
1
clinical benefit
1
time to disease progression
1
event free survival
1
overall response rate in both arms
1
14 more recorded rows
time to progression expert evaluation committee assessment
1
clinical response
1
overall survival
1
progression free survival
1
clinical response rate
1
5 year disease free survival
1
pfs in hemoglobin a1c less than 5 7 at baseline
1
pathological response for basal group 2
1
safety
1
clinical benefit response rate
1
who died
1
progression free survival based on independent radiologist
1
adverse drug reaction
1
dose limiting toxicity
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Exemestane's 50 ongoing trials reports first?
"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)"; n 10273; "5-year Disease-free Survival"; 2030-09-30
NCT01272037
"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer"; n 5018; "Invasive Disease-Free Survival (IDFS)"; 2027-01-08
NCT01674140
"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer"; n 1939; "Invasive Disease-Free Survival (IDFS)"; 2030-01
NCT02057133
"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread"; n 198; "Number of Participants with One or More Drug-Related Adverse Events"; 2026-12
NCT02115282
"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic"; n 608; "Progression-free Survival (PFS)"; 2027-06-02
NCT02476786
"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score"; n 50; "Response rate"; 2032-07-31
14 further recorded trials
NCT02603679
"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases"; n 181; "Radiological Objective Response Rate after Completion of the First 12-week Period of Primary Medical Treatment"; 2031-12-31
NCT02947685
"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer"; n 518; "Progression-free Survival (PFS) as Assessed by Investigator"; 2026-07-31
NCT04569747
"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer"; n 393; "Invasive Disease Free Survival at 3 Years"; 2030-09-01
NCT04906395
"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer"; n 250; "Suppression of ovarian function"; 2026-04-30
NCT04975308
"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer"; n 874; "Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)"; 2027-08
NCT04985266
"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer"; n 1100; "Incidence of positive ctDNA result during surveillance (Surveillance phase)"; 2030-09-01
NCT05306340
"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)"; n 373; "Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population"; 2026-10-15
NCT05467891
"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer"; n 200; "Recurrence Free Survival (RFS)"; 2029-08-15
NCT05512364
"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)"; n 220; "Distant metastasis free survival (DMFS)"; 2035-11-01
NCT05514054
"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer"; n 8000; "Invasive Disease-Free Survival (IDFS)"; 2032-03
NCT05573126
"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer"; n 95; "Incidence of dose-limiting toxicities (DLTs) during Cycle 1 of EP0062 treatment"; 2028-02
NCT05645536
"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study"; n 250; "The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)"; 2030-03
NCT05768139
"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors"; n 880; "Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)"; 2030-07
NCT05774951
"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy"; n 4300; "Invasive breast cancer-free survival (IBCFS)"; 2036-05-29
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Exemestane could settle lifespan?
NCT02947685 measures Progression-free Survival (PFS) as Assessed by Investigator, reading out 2026-07-31.
27 open trials; n 518; "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer"
Show the evidence
Trial
NCT02947685
"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer"; n 518; "Progression-free Survival (PFS) as Assessed by Investigator"; 2026-07-31
NCT05890287
"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy"; n 60; "Progression-free survival"; 2026-10-01
NCT05306340
"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)"; n 373; "Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population"; 2026-10-15
NCT01272037
"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer"; n 5018; "Invasive Disease-Free Survival (IDFS)"; 2027-01-08
NCT02115282
"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic"; n 608; "Progression-free Survival (PFS)"; 2027-06-02
NCT04975308
"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer"; n 874; "Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)"; 2027-08
14 further recorded trials
NCT06979596
"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)"; n 250; "Progression-Free Survival (PFS) - All Cohorts"; 2027-11-04
NCT07024173
"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer"; n 240; "Progression free survival (PFS) evaluated by the blinded independent central review (BICR)."; 2027-12
NCT06105632
"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment"; n 333; "Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"; 2028-01-21
NCT06680921
"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)"; n 482; "Progression free survival(PFS) , as assessed by blinded independent review committee(BIRC) according to RECIST1.1"; 2028-08-31
NCT06428396
"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)"; n 120; "Progression-free Survival (PFS)"; 2028-12-25
NCT05826964
"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer"; n 24; "Progression-Free Survival 1 (PFS1) Among Participants in Step 2"; 2029-07-31
NCT07391774
"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial"; n 1978; "Invasive breast cancer-free survival (iBCFS)"; 2029-07-31
NCT05467891
"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer"; n 200; "Recurrence Free Survival (RFS)"; 2029-08-15
NCT01674140
"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer"; n 1939; "Invasive Disease-Free Survival (IDFS)"; 2030-01
NCT04569747
"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer"; n 393; "Invasive Disease Free Survival at 3 Years"; 2030-09-01
NCT05827081
"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer"; n 1400; "Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years"; 2030-09-20
NCT00310180
"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)"; n 10273; "5-year Disease-free Survival"; 2030-09-30
NCT07062965
"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment."; n 400; "Progression Free Survival (PFS) as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"; 2030-11-04
NCT05891093
"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)"; n 766; "invasive disease free survival (iDFS)"; 2031-05-31
Q10
Which 49 trials of Exemestane posted no result?
Posted no result
49 of 49 completed trials
Registrations
NCT00031889, NCT01331447, NCT01331421, NCT01331434, NCT00525096 and NCT00919399, and 43 more
Completion dates
oldest 2002-06; newest 2024-07-05
Show the evidence
Trial
NCT00031889
2002-06
NCT01331447
2004-05
NCT01331421
2004-08
NCT01331434
2004-10
NCT00525096
2004-12
NCT00919399
2006-06
14 further recorded trials
NCT00174343
2006-09
NCT00649090
2007-04
NCT00261027
2007-09
NCT01965080
2009-02
NCT00066586
2009-02-10
NCT00032136
2009-04
NCT00279448
2009-06
NCT00016432
2011-02
NCT00944918
2011-06
NCT01004081
2011-10
NCT00933309
2012-08
NCT01553903
2013-05
NCT01234857
2013-10-15
NCT01626222
2013-11
Q11
At the median, Exemestane's trials enrolled 110 people — anything larger?
Median enrolment
110
Largest enrolment
10273
Registered trials counted
235
Q12
What do 10559 spontaneous reports say about Exemestane — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Exemestane appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 10559 reaction mentions were counted: malignant neoplasm progression 1687; fatigue 1437; arthralgia 1386; neutropenia 1371. open-targets-adr · CHEMBL1200374 · 2026-06-24
Show the evidence
malignant neoplasm progression
1687
fatigue
1437
arthralgia
1386
neutropenia
1371
metastases to bone
932
disease progression
792
4 more recorded rows
neoplasm progression
774
breast cancer
743
metastases to liver
743
breast cancer metastatic
694
recorded 2026-06-24 · last checked 2026-09-04
Q13
Exemestane and CYP3A4 and CYP1A2: shared by which compounds?
CYP3A4 and CYP1A2 appear in Exemestane's recorded interaction sentences, 4 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2pharmacokinetics
Drug Interaction Studies Exemestane does not inhibit any of the major CYP isoenzymes, including CYP 1A2, 2C9, 2D6, 2E1, and 3A4.
CYP3A4
pharmacokinetics
Studies using human liver preparations indicate that cytochrome P 450 3A4 (CYP 3A4) is the principal isoenzyme involved in the oxidation of exemestane.
pharmacokinetics
In a pharmacokinetic interaction study of 10 healthy postmenopausal volunteers pretreated with potent CYP 3A4 inducer rifampicin 600 mg daily for 14 days followed by a single dose of exemestane 25 mg, the mean plasma C max and AUC 0-∞ of exemestane were decreased by 41% and 54%, respectively [see Dosage and Administration (2.2) and Drug Interactions (7) ] .
pharmacokinetics
In a clinical pharmacokinetic study, coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Exemestane studied with fasting?
fasting is named in Exemestane's label sentences: "We conducted a prospective observational study to test the associations between SNPs in candidate genes in estrogen signaling and aromatase inhibitor metabolism pathways with fasting lipid profiles during the first 3 months of aromatase inhibitor therapy in postmenopausal women with early breast…" openfda-label+europepmc · 2026-08-30
1 recorded statement; fasting
Show the evidence
fasting
We conducted a prospective observational study to test the associations between SNPs in candidate genes in estrogen signaling and aromatase inhibitor metabolism pathways with fasting lipid profiles during the first 3 months of aromatase inhibitor therapy in postmenopausal women with early breast cancer randomized to adjuvant letrozole or exemestane.
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Exemestane and mTOR?
"Clones resistant to both letrozole and exemestane demonstrated PIK3CA/AKT/mTOR signaling activation, KRAS pathway dysregulation, hedgehog signaling, and androgen receptor pathways, alongside extensive immune activation and metabolic reprogramming." — where Exemestane and mTOR appear together. Europe PMC · pathway abstract search · 2025-11-01
"Clones resistant to both letrozole and exemestane demonstrated PIK3CA/AKT/mTOR signaling activation, KRAS pathway dysregulation, hedgehog signaling, and androgen receptor pathways, alongside extensive immune activation and metabolic reprogramming."
PMID 41260207
"Everolimus is an mammalian target of rapamycin (mTOR) inhibitor used in combination with exemestane for metastatic ER+BC."
PMID 37644396
"The Medline, Embase and Cochrane Library databases were searched for randomized trials comparing CDK4/6 inhibitors, PI3K/mTOR inhibitors, or HDAC inhibitors vs. placebo with the addition of exemestane or fulvestrant as second-line treatments in patients with HR + advanced breast cancer up to December 16, 2021."
NAD+PMID 28770670
"In BV-2 microglial cells, exemestane activated the transcription factor Nrf2 and induced expression of the Nrf2-dependent genes that encode the antioxidant enzymes NAD(P)H: quinone oxidoreductase 1, haem oxygenase-1, and glutamylcysteine ligase."
IGF-1PMID 28681171
"R/D/E did not improve PFS compared with R/E. Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (from overlapping toxicities with IGF1R inhibitor) contributed to lack of improved PFS."
recorded 2025-11-01 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.